Alyeska Investment Group
ROIV icon

Alyeska Investment Group’s Roivant Sciences ROIV Stock Holding History

Alyeska Investment Group’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-325,992
Closed -$3.29M – 607
2023
Q2 		$3.29M Hold
325,992
– – 0.02% 368
2023
Q1 		$2.41M Buy
+325,992
New +$2.68M 0.02% 343

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alyeska Investment Group's ROIV Position: Q4 2025 in Review

Alyeska Investment Group sold out of Roivant Sciences (ROIV) in Q4 2025, closing a stake of 494,455 shares — an estimated $7.48M sold.

Alyeska Investment Group first reported a position in ROIV in Q4 2022 and held it in 7 quarters. The position peaked at $11.5M in Q3 2024. 398 funds tracked by Wall St. Rank hold ROIV as of Q4 2025.

  • Alyeska Investment Group reported no remaining Roivant Sciences position as of Q4 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 494,455 Roivant Sciences shares in Q4 2025, an estimated $7.48M.
  • Alyeska Investment Group first reported a position in Roivant Sciences in Q4 2022 and held it in 7 quarters.
  • Alyeska Investment Group's Roivant Sciences position peaked at $11.5M in Q3 2024.
  • 398 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2025.

Based on Alyeska Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.